Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Kidney Problems More Prevalent in Patients with Rheumatoid Arthritis

  |  Issue: September 2014  |  

When looking at the risk of developing CVD in patients with reduced kidney function, the study found that RA patients with more advanced kidney disease (eGFR <45 mL/min/1.73 m2) had a significant increased risk of developing CVD (HR, 1.93; 95% CI, 1.04–3.58; P=0.04). No significant association was found between eGFR <60 mL/min/1.73 m2 and the development of CVD in either cohort.

Monitor Patients Closely

Along with close monitoring of kidney function and controlling the underlying inflammatory disease, Dr. Matteson encouraged rheumatologists to help advise patients to use nonsteroidal antiinflammatory drugs (NSAIDs) sparingly.

ADVERTISEMENT
SCROLL TO CONTINUE

Mary Beth Nierengarten is a freelance medical journalist based in St. Paul, Minn.

Reference

  1. Hickson LJ, Crowson CS, Gabriel SE, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014 Feb;63(2):206–213.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

    Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

    Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients

    In a controlled, large-cohort, longi­tudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1  This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…

    Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus

    WASHINGTON, D.C.—Experts at the 2016 ACR/ARHP Annual Meeting session, Systemic Lupus Erythematosus—Clinical Aspects and Treatment IV: Biomarkers, reported on a number of recent studies showing advancement in our understanding of the disease mechanisms underlying systemic lupus erythematosus (SLE) that place these patients at risk for cardiovascular disease (CVD) and other comorbidities. Mechanisms of CVD Risk…

    Study Finds Renal Arteriosclerosis Is Common in Lupus Nephritis Patients

    Renal arteriosclerosis is common in lupus patients with nephritis and occurs two decades earlier than it does in people without lupus nephritis (LN), report investigators in a study that examined the prevalence of renal arteriosclerosis in LN patients compared with healthy controls.1  The finding suggests that renal arteriosclerosis could be used as a biomarker for…